Scholar Rock (NASDAQ:SRRK) Cut to Peer Perform at Wolfe Research

Wolfe Research downgraded shares of Scholar Rock (NASDAQ:SRRK) from an outperform rating to a peer perform rating in a research report report published on Thursday, Marketbeat reports.

Several other research analysts have also issued reports on the stock. Citigroup lifted their price target on shares of Scholar Rock from $60.00 to $74.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Piper Sandler increased their price objective on Scholar Rock from $60.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, September 15th. Evercore reissued an “outperform” rating and set a $72.00 price objective on shares of Scholar Rock in a research note on Tuesday, September 15th. Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday. Finally, Truist Financial lifted their target price on Scholar Rock from $76.00 to $77.00 and gave the stock a “buy” rating in a report on Thursday, September 24th. Three investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $67.67.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $43.21 on Thursday. Scholar Rock has a twelve month low of $34.25 and a twelve month high of $61.76. The company has a current ratio of 5.41, a quick ratio of 7.02 and a debt-to-equity ratio of 1.16. The company has a 50-day moving average of $46.13 and a 200-day moving average of $48.22. The firm has a market cap of $5.27 billion, a price-to-earnings ratio of -12.86 and a beta of 0.78.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Tuesday, November 10th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.30 million. During the same quarter in the previous year, the firm earned ($0.90) earnings per share. Analysts forecast that Scholar Rock will post -3.04 earnings per share for the current fiscal year.

Insider Activity at Scholar Rock

In other news, Director Srinivas Akkaraju acquired 146,970 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The stock was purchased at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the purchase, the director owned 6,380,517 shares of the company’s stock, valued at approximately $265,365,702.03. This trade represents a 2.36% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 10.30% of the company’s stock.

Institutional Trading of Scholar Rock

Hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC boosted its position in Scholar Rock by 484.5% during the second quarter. Squarepoint Ops LLC now owns 291,996 shares of the company’s stock valued at $16,060,000 after purchasing an additional 242,041 shares during the last quarter. Nicholas Investment Partners LP purchased a new position in Scholar Rock in the second quarter valued at about $4,968,000. Senator Investment Group LP purchased a new position in Scholar Rock in the second quarter valued at about $11,275,000. BlackRock Inc. acquired a new position in Scholar Rock in the 2nd quarter worth about $522,175,000. Finally, Legal & General Group Plc acquired a new position in Scholar Rock in the 2nd quarter worth about $3,363,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Recent Scholar Rock Headlines

Here are a few of the latest headlines about SRRK:

• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to a loss of $0.75 from $0.78 and its FY2026 estimate to a loss of $3.23 from $3.30. The firm maintained its Buy rating and $70 price target. HC Wainwright Predicts Scholar Rock Q1 Earnings
• Negative Sentiment: Wolfe Research downgraded SRRK from Outperform to Peer Perform, removing a bullish rating signal. Wolfe Research ratings
• Negative Sentiment: HC Wainwright cut estimates for FY2027–FY2030: its FY2029 forecast shifted from $0.47 in earnings per share to a $0.12 loss, while its FY2030 forecast fell from $1.44 to $1.00. These longer-range cuts temper the improved near-term outlook. Scholar Rock analyst estimates

About Scholar Rock

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.